Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited has announced the appointment of Mr. Ken Lim as the new Chief Financial Officer, effective October 7, 2025, succeeding Ms. Joy Linton, who will retire after a transition period. Mr. Lim, previously the Chief Strategy Officer, brings over a decade of experience at CSL, and his appointment reflects the company’s strong executive talent pool. This leadership change is expected to maintain CSL’s strategic direction and continue delivering value to its stakeholders.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company based in Melbourne, Australia. The company is involved in the development and delivery of innovative biotherapies and influenza vaccines, focusing on providing life-saving medicines and vaccines to people worldwide.
YTD Price Performance: -29.66%
Average Trading Volume: 1,146,758
Technical Sentiment Signal: Sell
Current Market Cap: A$94.23B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.